Bladder Cancer Clinical Trial

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States

Summary

Multi-center, prospective non-interventional study to collect data on the early use of ADSTILADRIN in the US. Data will be collected from participants, caregivers and prescribing physicians in a real-world setting.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Prescribed and scheduled treatment with ADSTILADRIN per physician discretion or received the first instillation of ADSTILADRIN per physician discretion after 5 September 2023 but prior to site activation
Signed and dated ICF.
Age 18 years or older at day ICF is signed.

Exclusion Criteria:

Currently enrolled in a clinical trial.
Participants who have previously been treated with ADSTILADRIN in the context of a clinical trial
Participant is pregnant or breastfeeding.

Study is for people with:

Bladder Cancer

Estimated Enrollment:

800

Study ID:

NCT06026332

Recruitment Status:

Recruiting

Sponsor:

Ferring Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 20 Locations for this study

See Locations Near You

Ferring Investigational Site
Gilbert Arizona, 85234, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
Little Rock Arkansas, 72211, United States
Ferring Investigational Site
Los Angeles California, 90033, United States
Ferring Investigational Site
Gainesville Florida, 32608, United States
Ferring Investigational Site
Atlanta Georgia, 30328, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
Greenwood Indiana, 46143, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
Jeffersonville Indiana, 47130, United States
Ferring Investigational Site
Wichita Kansas, 67226, United States
Ferring Investigational Site
Baltimore Maryland, 21287, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
Rochester Minnesota, 55905, United States
Ferring Investigational Site
Omaha Nebraska, 68114, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
Bronx New York, 10467, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
New York New York, 10032, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
Syracuse New York, 13210, United States
Ferring Investigational Site
Gahanna Ohio, 43230, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
Myrtle Beach South Carolina, 29572, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
Nashville Tennessee, 37209, United States
Ferring Investigation Site
Dallas Texas, 75390, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
Charlottesville Virginia, 22908, United States More Info
Global Clinical Compliance
Contact
Ferring Investigational Site
Virginia Beach Virginia, 23462, United States

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Estimated Enrollment:

800

Study ID:

NCT06026332

Recruitment Status:

Recruiting

Sponsor:


Ferring Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider